Tumor
Activity Concentration (Bq/mL)
hours post inj
0
10
20
30
40
50
60
70
80
90
100
J591
PSMA617
PSMA617+J591
PSMA617 J591 SUM

FIG. 1

Uptake of Lu-177 in LNCaP
(mean of each group)
CPM/mg
40000
35000
30000
25000
20000
15000
10000
5000
0
36,708
16,777
7,536
1
2
3
Treatment Group, autopsy tumor cpm/mg 3 days post-injection
+48% > than the sum
of the individual agents
Sum of groups 1+2= 24,313
autopsy measurement of cpm/mg tumor
3 days post-injection
1= J591-Lu177; 2= 617-Lu177; 3= J591-Lu177 + 617-Lu177

FIG. 2

Group 3:
J591-Lu177
+ 617-Lu177
combination
% greater than
sum-of-the-parts
CWR
LNCaP
PC3/PSMA
In all 3 PC models tested, the
Radiation dose to tumor from
the combination was 44-65%
Greater than the sum of its parts.
+65%
+44%
+50%
Group 2:
617-Lu177
only
Group 1:
J591-Lu177
only
COMBO
PSMA617
J591
4800
4200
3600
3000
2400
1800
1200
600
0

FIG. 3




Tumor
Activity Concentration (Bq/mL)
100
90
80
70
60
50
40
30
20
10
0
0
10
20
30
40
50
60
70
80
hours post inj
J591
PSMA617
PSMA617+J591
PSMA617 J591 SUM

FIG. 1



1= J591-Lu^{177}; 2= 617-Lu^{177}; 3= J591-Lu^{177} + 617-Lu^{177}

FIG. 2



Group 3: J591-Lu177 + 617-Lu177 combination
4500
4000
3500
3000
2500
2000
1500
1000
500
0
cGy
Group 1:
J591-Lu177
only
Group 2:
617-Lu177
only
50%
+65%
+44%
% greater than sum-of-the-parts
CWR
LNCaP
PC3/PSMA
J591
PSMA617
COMBO
In all 3 PC models tested, the Radiation dose to tumor from the combination was 44-65% Greater than the sum of its parts

FIG. 3